File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Alternative and rescue treatment regimens for Helicobacter pylori eradication

TitleAlternative and rescue treatment regimens for Helicobacter pylori eradication
Authors
Issue Date2002
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2002, v. 3 n. 9, p. 1301-1311 How to Cite?
AbstractEradication therapy has been incorporated into clinical practice. The regimens currently recommended for first-line treatment include a 2-week bismuth-based triple therapy (mainly in developing countries), a 1 - 2 week proton pump inhibitor (PPI)-based triple therapy and a 1-week ranitidine bismuth citrate (RBC)-based triple therapy. However, these regimens fail to eradicate Helicobacter pylori in up to 20% of patients due to poor compliance, inadequate treatment duration, smoking, old age and bacterial resistance to nitroimidazoles and/or macrolides in particular. Therefore, alternative regimens that avoid nitroimidazoles and/or macrolides or overcome bacterial resistance to these drugs, improve compliance, minimise side effects and/or reduce costs have been evaluated. One-week quadruple therapy, which adds a PPI or histamine receptor 2-blocker to bismuth-based triple therapy, usually achieves an eradication rate of 90% when used as an alternative first-line therapy but the efficacy decreases when used as a rescue therapy. Several new triple therapies that may be used as alternative and/or rescue therapies have been evaluated. Among these are furazolidone-based (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC), fluoroquinolone-based (levofloxacin or moxifloxacin plus an antibiotic and a PPI) and ecabet sodium-based (ecabet plus two antibiotics) triple therapies. Recently, rifabutin has been used in combination with a PPI and amoxycillin as a rescue therapy, with satisfactory eradication rates. In addition, a number of new antimicrobial agents are currently under investigation in in vitro studies but the clinical values of these agents needs to be confirmed.
Persistent Identifierhttp://hdl.handle.net/10722/162631
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
References

 

DC FieldValueLanguage
dc.contributor.authorXia, HHXen_US
dc.contributor.authorWong, BCYen_US
dc.contributor.authorTalley, NJen_US
dc.contributor.authorLam, SKen_US
dc.date.accessioned2012-09-05T05:21:52Z-
dc.date.available2012-09-05T05:21:52Z-
dc.date.issued2002en_US
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2002, v. 3 n. 9, p. 1301-1311en_US
dc.identifier.issn1465-6566en_US
dc.identifier.urihttp://hdl.handle.net/10722/162631-
dc.description.abstractEradication therapy has been incorporated into clinical practice. The regimens currently recommended for first-line treatment include a 2-week bismuth-based triple therapy (mainly in developing countries), a 1 - 2 week proton pump inhibitor (PPI)-based triple therapy and a 1-week ranitidine bismuth citrate (RBC)-based triple therapy. However, these regimens fail to eradicate Helicobacter pylori in up to 20% of patients due to poor compliance, inadequate treatment duration, smoking, old age and bacterial resistance to nitroimidazoles and/or macrolides in particular. Therefore, alternative regimens that avoid nitroimidazoles and/or macrolides or overcome bacterial resistance to these drugs, improve compliance, minimise side effects and/or reduce costs have been evaluated. One-week quadruple therapy, which adds a PPI or histamine receptor 2-blocker to bismuth-based triple therapy, usually achieves an eradication rate of 90% when used as an alternative first-line therapy but the efficacy decreases when used as a rescue therapy. Several new triple therapies that may be used as alternative and/or rescue therapies have been evaluated. Among these are furazolidone-based (furazolidone plus an antibiotic and a bismuth salt, a PPI or RBC), fluoroquinolone-based (levofloxacin or moxifloxacin plus an antibiotic and a PPI) and ecabet sodium-based (ecabet plus two antibiotics) triple therapies. Recently, rifabutin has been used in combination with a PPI and amoxycillin as a rescue therapy, with satisfactory eradication rates. In addition, a number of new antimicrobial agents are currently under investigation in in vitro studies but the clinical values of these agents needs to be confirmed.en_US
dc.languageengen_US
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_US
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_US
dc.subject.meshAnti-Bacterial Agentsen_US
dc.subject.meshComplementary Therapies - Methodsen_US
dc.subject.meshDrug Therapy, Combination - Pharmacology - Therapeutic Useen_US
dc.subject.meshHelicobacter Infections - Drug Therapyen_US
dc.subject.meshHelicobacter Pylori - Drug Effectsen_US
dc.subject.meshHumansen_US
dc.titleAlternative and rescue treatment regimens for Helicobacter pylori eradicationen_US
dc.typeArticleen_US
dc.identifier.emailWong, BCY:bcywong@hku.hken_US
dc.identifier.authorityWong, BCY=rp00429en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1517/14656566.3.9.1301en_US
dc.identifier.pmid12186623-
dc.identifier.scopuseid_2-s2.0-0036724705en_US
dc.identifier.hkuros81312-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0036724705&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume3en_US
dc.identifier.issue9en_US
dc.identifier.spage1301en_US
dc.identifier.epage1311en_US
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridXia, HHX=8757161400en_US
dc.identifier.scopusauthoridWong, BCY=7402023340en_US
dc.identifier.scopusauthoridTalley, NJ=36045241200en_US
dc.identifier.scopusauthoridLam, SK=7402279473en_US
dc.identifier.citeulike3813498-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats